- Joined
- Apr 23, 2013
- Messages
- 6,525
- Display Name
Display name:
3G
I’m not trying to touch the third rail of COVID with this. The Lancet published this article, Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext
Knowing the FAAs position on SSRIs in general, and fluvoxamine specifically, I assume that even if there was FDA approval, this is not a treatment path an aviator would not want to take.
Curious to hear thoughts from @bbchien or @lbfjrmd.
https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext
Knowing the FAAs position on SSRIs in general, and fluvoxamine specifically, I assume that even if there was FDA approval, this is not a treatment path an aviator would not want to take.
Curious to hear thoughts from @bbchien or @lbfjrmd.